DynPort secures $32.3 million service contract from the NIAID
This article was originally published in Scrip
DynPort Vaccine has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US NIH, to establish and operate a Phase I clinical trial unit for infectious disease therapeutics. The contract is valued at approximately $32.3 million over seven years. DynPort will team up with Quintiles Transnationalto complete the project. Under the agreement, DynPort and Quintiles will assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. DynPort will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase I clinical research and support services. Work will be performed by DynPort at its headquarters in Maryland.